Solid Tumors Clinical Trial
Official title:
Phase I Trial of ZIO-101 in Patients With Solid Tumors
Primary Objectives:
1. To determine the toxicities and maximum tolerated dose (MTD) of ZIO-101 when
administered intravenously once a day for 5 consecutive days every 4 weeks in subjects
with advanced solid tumors.
2. To determine the pharmacokinetic profile of ZIO-101 when administered intravenously
once a day for 5 consecutive days every 4 weeks.
Secondary Objective:
1. To determine the anti-tumor effects of ZIO-101.
ZIO-101 is a drug that may change cancerous cells into healthy (benign) cells. It is also
designed to cause cancer cells to destroy themselves; a term called apoptosis.
Before you can start treatment on this study, you will have what are called "screening
tests" no more than one week before starting the study. These tests will help the doctor
decide if you are eligible to take part in the study. You will have a complete medical
history and physical exam, including measurements of your weight, blood pressure, pulse, and
temperature. You will also be asked what other medicines you are taking and about your
general well-being. You will have an electrocardiogram (ECG - a test to measure the
electrical activity of the heart). Blood (about 2 1/2 tablespoons) will be drawn. A sample
of urine will be also be collected and tested to see if your kidneys are working correctly.
Women who are able to have children must have a negative urine pregnancy test.
To see the current condition of your tumor, additional tests may need to be performed if
they have not already been done recently. These tests may include a chest x-ray, a CT scan
(imaging computer pictures of your body), a bone scan (an imaging test of your bones with a
contrast material), or an MRI (a detailed imaging scan of certain areas of your body).
If you are found to be eligible to take part in this study, you will begin treatment with
ZIO-101. Immediately before being treated with ZIO-101 on Day 0, you will have another
physical exam and you will be asked about any medicines you are taking and how you are
feeling. You will also be asked a series of questions which will assess your mental health.
This is called a mini-mental status exam and will take approximately 10 minutes to complete.
The blood tests may need to be repeated along with the ECG and the urine test. In addition,
a small blood sample (about 10 teaspoons) must be taken immediately before the injection of
ZIO-101. This blood will be used to help in the measurement of drug levels in the blood.
These are called pharmacokinetic (PK) tests. This blood sample will also be used to measure
arsenic levels in your blood.
ZIO-101 will be injected into your vein over 60 minutes in the clinical translational
research center of UTMDACC. This drug must be given through a special IV called a central
line catheter so that it does not damage your surrounding tissue. You will have to sign a
separate consent document before placement of a catheter can be performed. Special care will
be taken to be sure the drug does not leak into surrounding tissue. The use of anti-nausea
and other supportive care medications may be given during the infusion.
Following the injection, you will have 6 samples of blood taken for PK tests at half an hour
and 1, 2, 4, 8, and 12 hours after finishing the treatment.
For the next 4 days at about the same time as your first infusion, you will be prepared for
treatment with ZIO-101. Before each injection, you will be asked how you feel, an ECG will
be performed, and a small sample of blood (about 2 teaspoons) will be drawn for PK tests.
The Day 1-4 infusions will also each take about 1 hour. In total you will receive 5 daily
injections of ZIO-101. On Day 4 at the end of the infusion, another sample of blood will be
drawn (about 5 teaspoons) to measure arsenic levels in your blood.
Your next visit will be Week 2 and at the start of this visit, a blood sample (about 2
teaspoons) will be drawn for PK tests, and you will be asked how you feel. At Week 3,
another blood sample (about 7 teaspoons) will be drawn for PK tests, and to measure arsenic
levels in your blood, and you will again be asked how you feel.
At Week 4, a new cycle begins. Immediately before being treated with ZIO-101, you will have
a physical examination and you will take a mini-mental status examination; you will be asked
about any medicines you are taking and how you are feeling. The blood tests will be repeated
along with the ECG and the routine urine test. In addition, tests to measure your tumor will
be repeated.
This study is trying to find the best dose of ZIO-101. At first, 3 patients will be assigned
to the first dose level. They will be followed to evaluate their side effects for a period
of 4 weeks before 3 more patients are enrolled. If none of the patients develop serious side
effects, the dose escalation will continue. If 1 of the 3 patients in a particular dose
level develops significant side effects, 3 more patients will be enrolled at that level. If
2 or more of the 6 patients develop serious side effects, then the escalation will finish
and all future patients on this study will be treated at a lower dose level (half way
between this level and the previous one).
You may receive up to 6 cycles of treatment. You may be taken off study early if your
disease gets worse or intolerable side effects occur. Once you go off study, you will have
an end of study visit. During this visit, you will have a physical exam, a mini-mental
status exam and blood (about 3 teaspoons) will be drawn for routine tests.
This is an investigational study. ZIO-101 has been authorized by the FDA for use in research
only. ZIO-101 will be provided free of charge during the study. Also, any tests or
procedures that are being done solely for the purpose of this research study will be
provided free of charge. Up to 50 patients will take part in this multicenter study. All
will be enrolled at M. D. Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
| Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
| Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
| Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
| Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT01940601 -
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
|
Phase 2 |